Ph.D. Michael Exton - 12 Feb 2026 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)

Role: Chief Executive Officer, Director
Signature: /s/ Michael Exton, Ph.D.
Issuer symbol: LXRX
Transactions as of: 12 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 17 Feb 2026, 16:05:31 UTC
Previous filing: 18 Feb 2025
Next filing: 03 Mar 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Exton Michael	Chief Executive Officer, Director	2445 TECHNOLOGY FOREST BLVD, 11TH FLOOR, THE WOODLANDS	/s/ Michael Exton, Ph.D.	17 Feb 2026	0002029249

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	LXRX	Restricted Stock Units	Award	$0	+862,440		$0.000000	862,440	12 Feb 2026	Common Stock	862,440		Direct	F1, F2
transaction	LXRX	Stock Option (Right to Buy)	Award	$0	+1,293,670		$0.000000	1,293,670	12 Feb 2026	Common Stock	1,293,670	$1.37	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock.
F2	Restricted stock units vest with respect to 1/3 of the shares subject to the restricted stock units on February 28 of each of the three years following the year of grant.
F3	Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant, and vests 1/48th per month for each month of service thereafter.